Cuantificación del antígeno de superficie del virus de la hepatitis B: implicaciones clínicas

Medicina Clinica - Tập 138 - Trang 483-488 - 2012
Maria Buti1,2, Francisco Rodríguez Frías3,2, Rafael Esteban1,2
1Servicio de Hepatología, Hospital Universitario Vall d’Hebron, Barcelona, España
2CIBEREHD del Instituto Carlos III, Barcelona, España
3Servicio de Bioquímica. Hospital Universitario Vall d’Hebron. Barcelona. España

Tài liệu tham khảo

Blumberg, 1965, A «new» antigen in leukemia sera, JAMA, 191, 541, 10.1001/jama.1965.03080070025007 Rotman Y, Brown AT, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology. 2009 (5 Suppl); 49:S22–27 Seeger, 2000, Hepatitis B virus biology, Microbiol Mol Biol Rev, 64, 51, 10.1128/MMBR.64.1.51-68.2000 Simon, 1988, Secreted hepatitis B surface antigen polypeptides are derived from transmembrane precursor, J Cell Biol, 107, 2163, 10.1083/jcb.107.6.2163 De Medina, 1988, The S promoter of HBV is regulated by positive and negative elements, Mol Cell Biol, 8, 2449, 10.1128/MCB.8.6.2449 Stibbe, 1983, Structural relationship between minor and major proteins of hepatitis B surface antigen, J Virol, 46, 626, 10.1128/JVI.46.2.626-628.1983 Heermann, 1984, Large surface proteins of HBV containing the Pre-s sequence, J Virol, 52, 396, 10.1128/JVI.52.2.396-402.1984 Dienes, 1990, Hepatic expression patterns of the large and middle hepatitis B surface proteins in viremic and non viremic chronic hepatitis B, Gastroenterology, 98, 1017, 10.1016/0016-5085(90)90028-Y Le Guillou, 2000, Evaluation of an enzyme-linked immunosorbent assay for detection and quantification of hepatitis B virus PreS1 envelope antigen in serum samples: comparison with two commercial assays for monitoring hepatitis B virus DNA, J Viral Hepat, 7, 387, 10.1046/j.1365-2893.2000.00248.x Wursthorn, 2011, Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum, J Clin Virol, 10.1016/j.jcv.2010.12.008 Lee, 2011, Quantification of HBsAg: Basic virology for clinical practice, World J Gastroenterol, 17, 283, 10.3748/wjg.v17.i3.283 Wiegand, 2008, A decline in hepatitis B virus surface antigen predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels, Antivir Ther, 13, 547, 10.1177/135965350801300402 Manesis, 2007, Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels, Antivir Ther, 12, 73, 10.1177/135965350701200107 Nguyen, 2009, The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B, Hepatol Int, 3 (Suppl 1), S5, 10.1007/s12072-009-9149-7 Wursthorn, 2006, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B, Hepatology, 44, 675, 10.1002/hep.21282 Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018 Perrillo, 2009, Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns, Hepatology, 49, 1063, 10.1002/hep.22932 Thompson, 2010, Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers, Hepatology, 51, 1933, 10.1002/hep.23571 Kimbi, 2005, Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B, World J Gastroenterol, 11, 6416, 10.3748/wjg.v11.i41.6416 Bill, 2004, Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration, Proc Natl Acad Sci USA, 101, 11135, 10.1073/pnas.0403925101 Nguyen, 2010, Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia, J Hepatol, 52, 508, 10.1016/j.jhep.2010.01.007 Jaroszewicz, 2010, Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective, J Hepatol, 52, 514, 10.1016/j.jhep.2010.01.014 Brunetto, 2010, Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers, Gastroenterology, 139, 483, 10.1053/j.gastro.2010.04.052 Brunetto, 2009, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B, Hepatology, 49, 1141, 10.1002/hep.22760 Moucari, 2009, Early serum HBsAg drop:a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients, Hepatology, 49, 1151, 10.1002/hep.22744 Chen, 2009, Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peginterferon-alpha-2a, Antiviral Res, 81, 88, 10.1016/j.antiviral.2008.09.005 Rijckborst, 2010, Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels, Hepatology, 52, 454, 10.1002/hep.23722 Sonneveld, 2010, Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline, Hepatology, 52, 1251, 10.1002/hep.23844 Gane, 2010, HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment [Abstract], J Hepatol, 52, S388, 10.1016/S0168-8278(10)61007-0 Liaw, 2009, 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B, Gastroenterology, 136, 486, 10.1053/j.gastro.2008.10.026 Wursthorn, 2010, Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients, Hepatology, 52, 1611, 10.1002/hep.23905